FERRING
15.2.2017 14:53:42 CET | Business Wire | Press release
Ferring today announced the recipients of the 2016-2017 Ferring Innovation Grants program, an annual initiative of the Ferring Research Institute (FRI) which provides grants of up to $100,000 for early stage research.
The program focuses on novel extracellular drug targets addressable with peptides or proteins within Ferring’s core therapeutic areas: reproductive health, gastroenterology, urology, and endocrinology.
The 2016-2017 awardees and their research subjects are:
Stuart Brierley - Flinders University, Australia
Venom-derived
NaV1.1 inhibitors as novel candidates for treating chronic visceral pain
associated with IBS
James Deane - Hudson Institute of Medical Research, Australia
Investigating
the requirement for Notch and Hedgehog signalling in the endometrial
stem/progenitor populations that cause endometriosis
Laurent Derré – Centre Hospitalier Universitaire Vaudois, Switzerland
Understanding
Siglec-related immunity in bladder cancer
Marie van Dijk - University of Amsterdam, Netherlands
ELABELA as
a potential biomarker and therapeutic for pre-eclampsia
Renjie Jin - Vanderbilt University Medical Center, USA
Sensitizing
castration-resistant prostate cancer to anti-androgens by targeting
gastrin-releasing peptide receptor
Florenta Kullmann - University of Pittsburgh, USA
Artemin: a
novel target for treatment of interstitial cystitis/bladder pain syndrome
Mireille Lahoud - Monash University, Australia
The development
of Clec12A-ligands as a therapeutic approach to regulate
gastrointestinal inflammation
Padma Murthi - Monash University, Australia
Investigating the
role of novel peptide receptor as an effective target to improve
placental function in preeclampsia
Markus Muttenthaler - The University of Queensland, Australia
Mapping
the location and function of oxytocin and vasopressin receptors
throughout the gut
Rodrigo Pacheco – Fundación Ciencia & Vida and Universidad Andres Bello,
Santiago, Chile
Targeting heteromers formed by G-protein coupled
receptors involved in the gut-homing of T-cells in inflammatory bowel
diseases
Aritro Sen – The University of Rochester, USA
Regulation of AMH
expression by GDF9+BMP15 and FSH during follicular development as a
novel therapeutic option
“We look forward to the outcomes of the research being carried out by our grant awardees,” said Keith James, President of FRI and Senior Vice President, Research and Development. “Ferring is committed to stimulating basic research, with the ultimate aim of developing innovative products that improve the lives of patients.”
Applications for the 2017-2018 Ferring Innovation Grants programme will open in spring/summer 2017. For more information on this year’s program, visit www.ferring-research.com/ferring-grants .
ENDS
About Ferring Research Institute Inc
Located in San Diego,
California Ferring Research Institute Inc. (FRI) is the global peptide
therapeutics research center for Ferring Pharmaceuticals. FRI is
committed to building a portfolio of novel, innovative peptide-based
drugs and biologicals to address the high unmet medical need for
patients in our therapeutic areas of interest. For more detailed
information please visit www.ferring-research.com
.
About Ferring Pharmaceuticals
Headquartered in Switzerland,
Ferring Pharmaceuticals is a research-driven, specialty
biopharmaceutical group active in global markets. The company
identifies, develops and markets innovative products in the areas of
reproductive health, urology, gastroenterology, endocrinology and
orthopaedics. Ferring has its own operating subsidiaries in nearly 60
countries and markets its products in 110 countries. To learn more about
Ferring or its products please visit www.ferring.com
.
View source version on businesswire.com: http://www.businesswire.com/news/home/20170215005630/en/
Contact:
Ferring Pharmaceuticals
Lindsey Rodger
Tel. +41 58 451 40 23
lindsey.rodger@ferring.com
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Charlotte Tilbury awarded CBE in the King’s Birthday Honours 202612.6.2026 23:31:00 CEST | Press release
Charlotte Tilbury CBE, sole Founder, President, Chairman and Chief Creative Officer of Charlotte Tilbury Beauty, has been awarded a Commander of the Order of the British Empire (CBE) in the King’s Birthday Honours 2026 for services to the beauty and cosmetics industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612679101/en/ Charlotte Tilbury, founder, president, chairman and chief creative officer of Charlotte Tilbury Beauty, who has been awarded a CBE (Commander of the Order of the British Empire) in 2026 for services to the beauty industry and entrepreneurship. (Photo: Charlotte Tilbury team) This honour recognises Charlotte’s contribution to leading and building Britain’s most successful global beauty brand. She has played a defining role in revolutionising the beauty industry and driving economic growth of the UK beauty sector, which has expanded from approximately £17bn in 2013 to over £31bn today. Charlotte Til
IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors12.6.2026 18:36:00 CEST | Press release
Venneman brings more than 30 years of digital transformation, AI, and enterprise technology experience as IQM prepares for its planned Nasdaq listing IQM Quantum Computers, the global leader in superconducting quantum computers, today announced the appointment of Barbara Venneman to its Board of Directors. Venneman deepens the Board's expertise in digital transformation, enterprise technology commercialization, and global business scaling as IQM expands its commercial footprint worldwide. Additionally, CEO and Co-founder Jan Goetz will replace Co-founder Juha Vartiainen as the Founder representative on the IQM Board. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612650938/en/ IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors Ms. Venneman joins the IQM Board of Directors following a distinguished career at the intersection of advanced technology, s
DEWA Organises Second Agentic AI Retreat at Al Shera’a, World’s Tallest, Largest and Smartest Net‑Positive Government Building12.6.2026 17:08:00 CEST | Press release
HE Saeed Mohammed Al Tayer, MD & CEO of Dubai Electricity and Water Authority (DEWA),has emphasised that DEWA deploys the latest Agentic AI technologies, in line with the vision to enhance its leading role and reinforce Dubai’s position as the city of the future. He made these remarks during the Agentic AI Executive Retreat DEWA organised at Al Shera’a, its new headquarters, which is the world’s tallest, largest and smartest net-positive government building. The event was attended by the executive leadership team and key stakeholders in digital transformation and artificial intelligence (AI), as well as representatives from SAP and McKinsey. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612633834/en/ DEWA organises second Agentic AI Retreat at Al Shera’a, world’s tallest, largest and smartest net positive government building (Photo: AETOSWire) In his speech, Al Tayer said that DEWA is guided by directives from the wise l
BeOne Medicines’ Foundational Hematology Franchise Leads Next Era of B-Cell Cancer Innovation at EHA 202612.6.2026 12:00:00 CEST | Press release
Tacabrutideg (BGB-16673, BTK degrader) showed durable responses in heavily pretreated R/R CLL and BTK inhibitor–naïve patients, signaling potential for earlier lines of treatmentBRUKINSA plus sonrotoclax (ZS) delivered deep, durable responses and high uMRD rates across TN CLL and R/R MCL and CLL, reinforcing its potential as an all-oral, fixed-duration treatment BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from its foundational hematology franchise at the 2026 European Hematology Association (EHA) Congress in Stockholm. Updated results from tacabrutideg (BGB-16673), a potential best-in-class Bruton’s tyrosine kinase (BTK) degrader, demonstrated durable responses in pretreated relapsed/refractory (R/R) chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), with early activity also seen in BTK inhibitor–naïve patients. These data are complemented by results from the all-oral combination of BRUKINSA® (zanubru
Cyviz: Microsoft’s Immersive Approach to Collaboration12.6.2026 09:00:00 CEST | Press release
At Microsoft’s Innovation Hub in Amsterdam, immersive technology is used to enable co-creation rather than one-way presentations. In the company’s Immersive Suite, customers, data experts, and technology specialists come together in a shared environment to address complex challenges more effectively. Watch Video Case Study >> This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612831180/en/ Watch Video Case Study >> https://www.cyviz.com/case-studies/microsoft-immersive-suite/ As business and technology environments grow more complex, establishing shared understanding across disciplines has become critical. The Immersive Suite is designed for active collaboration, where visual narratives, data, and technical content are explored interactively. This allows participants to test scenarios, align perspectives, and move more efficiently from discussion to decision. “We deliberately work with familiar tools like PowerPoint. That all
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom